NDF-RT Public Edition Release notes February 2012 NDF-RT (version name 2012.02.06) NDF-RT is now published on the first Monday of each month to coincide with the release date of RxNorm. This will better ensure that RxNorm_CUI and RxNorm_Name property values will remain up-to-date and in sync with monthly RxNorm content. Content in this version of NDF-RT represents refreshed NDF and RxNorm data, comprising the following changes based on December 2011 NDF content (patch 307) and full RxNorm release dated 1/3/2012. TOTAL CONCEPTS IN PREVIOUS VERSION (2012.01.03.11AB): 46665 VA Product concepts added: 41 Generic concepts added: 6 Ingredient concepts added: 6 VA Drug Interaction concepts added: 34 New concepts manually added for current version: 38 TOTAL CONCEPTS IN CURRENT VERSION (2012.02.06.11AB): 46790 The 38 new concepts manually added for this release included 3 added to the PE hierarchy, 2 added to the Chemical/Ingredient hierarchy, and 33 added to FDA Established Pharmacologic Classes. No concept name changes occurred for this release. ----------------------------------------------------------------- December 2011/January 2012 NDF-RT (version name 2012.01.03) NDF-RT is now published on the first Monday of each month to coincide with the release date of RxNorm. This will better ensure that RxNorm_CUI and RxNorm_Name property values will remain up-to-date and in sync with monthly RxNorm content. Content in this version of NDF-RT represents refreshed NDF and RxNorm data, comprising the following changes based on November 2011 NDF content (patch 304) and full RxNorm release dated 12/5/2011. This release also represents an update of the Disease/Finding and Chemical/Ingredient hierarchies based on MeSH Diseases and Chemicals (from the current version of MeSH available in the 2011AB version of the UMLS Metathesaurus): TOTAL CONCEPTS IN PREVIOUS VERSION (2011.11.07.11AA): 46044 VA Product concepts added: 111 VA Drug Class concepts added: 1 Generic concepts added: 29 Ingredient concepts added: 11 VA Drug Interaction concepts added: 289 RxNorm Dose Form concepts added: 1 New Chemical/Ingredient concepts added from MeSH Chemicals: 101 New Disease/Finding concepts added from MeSH Diseases: 86 MeSH Diseases concepts programmatically removed: 1 MeSH Chemicals concepts programmatically removed: 12 New concepts manually added for current version: 5 TOTAL CONCEPTS IN CURRENT VERSION (2012.01.03.11AB): 46665 The 5 new concepts manually added for this release included 3 added to the PE hierarchy, and 2 added to FDA Established Pharmacologic Classes. In addition, the following concept name changes occurred for this release. Biological Products [Chemical/Ingredient] was changed to Biological Agents [Chemical/Ingredient]; Epoetin Alfa [Chemical/Ingredient] was changed to epoetin alfa [Chemical/Ingredient]; Ferrosoferric Oxide [Chemical/Ingredient] was changed to Ferumoxytol [Chemical/Ingredient]; Flexibacteraceae Infections [Disease/Finding] was changed toCytophagaceae Infections [Disease/Finding]; Gas [Dose Form] was changed to Inhalant or Spray [Dose Form]; Gestational Trophoblastic Neoplasms [Disease/Finding] was changed to Gestational Trophoblastic Disease [Disease/Finding]; Indigotindisulfonate Sodium [Chemical/Ingredient] was changed to Indigo Carmine [Chemical/Ingredient]; insulin aspart [Chemical/Ingredient]was changed to Insulin Aspart [Chemical/Ingredient]; insulin LISPRO [Chemical/Ingredient]was changed to Insulin Lispro [Chemical/Ingredient]; Insulin, NPH [Chemical/Ingredient]was changed to Insulin, Isophane [Chemical/Ingredient]; Insulin, Protamine Zinc, Beef-Pork [Chemical/Ingredient] was changed to insulin, protamine zinc, beef-pork [Chemical/Ingredient]; Insulin, Regular, Beef-Pork [Chemical/Ingredient] was changed to insulin, regular, beef-pork [Chemical/Ingredient]; Interferon Alfa-2a [Chemical/Ingredient] was changed to interferon alfa-2a [Chemical/Ingredient]; Interferon Alfa-2b [Chemical/Ingredient] was changed to interferon alfa-2b [Chemical/Ingredient]; Interferon gamma-1b [Chemical/Ingredient] was changed tointerferon gamma-1b [Chemical/Ingredient]; Intervertebral Disk Degeneration [Disease/Finding] was changed to Intervertebral Disc Degeneration [Disease/Finding]; Intervertebral Disk Displacement [Disease/Finding] was changed to Intervertebral Disc Displacement [Disease/Finding]; Kangai-1 Protein [Chemical/Ingredient] was changed to Antigens, CD82 [Chemical/Ingredient]; LDL-Receptor Related Protein 1 [Chemical/Ingredient] was changed to Low Density Lipoprotein Receptor-Related Protein-1 [Chemical/Ingredient]; LDL-Receptor Related Protein 2 [Chemical/Ingredient] was changed to Low Density Lipoprotein Receptor-Related Protein-2 [Chemical/Ingredient]; Legg-Perthes Disease [Disease/Finding] was changed to Legg-Calve-Perthes Disease [Disease/Finding]; lopinavir [Chemical/Ingredient] was changed to Lopinavir [Chemical/Ingredient]; Mental Retardation [Disease/Finding] was changed to Intellectual Disability [Disease/Finding]; Mycobacterium Infections, Atypical [Disease/Finding] was changed to Mycobacterium Infections, Nontuberculous [Disease/Finding]; NADP Transhydrogenase [Chemical/Ingredient] was changed to NADP Transhydrogenases [Chemical/Ingredient]; NPH Insulin, Beef [Chemical/Ingredient] was changed to isophane insulin, beef [Chemical/Ingredient]; NPH Insulin, Beef-Pork [Chemical/Ingredient] was changed to isophane insulin, beef-pork [Chemical/Ingredient]; NPH Insulin, Human [Chemical/Ingredient] was changed to isophane insulin, human [Chemical/Ingredient]; NPH Insulin, Pork [Chemical/Ingredient] was changed to isophane insulin, pork [Chemical/Ingredient]; Regurgitation, Gastric [Disease/Finding] was changed to Laryngopharyngeal Reflux [Disease/Finding]; Sarcoma, Ewing's [Disease/Finding] was changed to Sarcoma, Ewing [Disease/Finding]; Tiapride [Chemical/Ingredient] was changed to Tiapamil Hydrochloride [Chemical/Ingredient]; Trenbolone [Chemical/Ingredient] was changed to Trenbolone Acetate [Chemical/Ingredient]; and triptorelin pamoate [Chemical/Ingredient] was changed to Triptorelin Pamoate [Chemical/Ingredient]. ----------------------------------------------------------------- November 2011 NDF-RT (version name 2011.11.07) NDF-RT is now published on the first Monday of each month to coincide with the release date of RxNorm. This will better ensure that RxNorm_CUI and RxNorm_Name property values will remain up-to-date and in sync with monthly RxNorm content. Content in this version of NDF-RT represents refreshed RxNorm data, comprising the following changes based on full RxNorm release dated 10/3/2011. TOTAL CONCEPTS IN PREVIOUS VERSION (2011.10.03.11AA): 46044 TOTAL CONCEPTS IN CURRENT VERSION (2011.11.07.11AA): 46044 No concept name changes occurred for this release. ----------------------------------------------------------------- October 2011 NDF-RT (version name 2011.10.03) NDF-RT is now published on the first Monday of each month to coincide with the release date of RxNorm. This will better ensure that RxNorm_CUI and RxNorm_Name property values will remain up-to-date and in sync with monthly RxNorm content. Content in this version of NDF-RT represents refreshed NDF and RxNorm data, comprising the following changes based on August 2011 NDF content (patch 290) and full RxNorm release dated 9/6/2011. TOTAL CONCEPTS IN PREVIOUS VERSION (2011.09.06.11AA): 45756 VA Product concepts added: 27 Generic concepts added: 4 Ingredient concepts added: 7 VA Drug Interaction concepts added: 242 New concepts manually added for current version: 8 TOTAL CONCEPTS IN CURRENT VERSION (2011.10.03.11AA): 46044 The 8 new concepts manually added for this release included 5 added to the MoA hierarchy and 3 added to FDA Established Pharmacologic Classes. No concept name changes occurred for this release. ----------------------------------------------------------------- September 2011 NDF-RT (version name 2011.09.06) NDF-RT is now published on the first Monday of each month to coincide with the release date of RxNorm. This will better ensure that RxNorm_CUI and RxNorm_Name property values will remain up-to-date and in sync with monthly RxNorm content. Content in this version of NDF-RT represents refreshed NDF and RxNorm data, comprising the following changes based on July 2011 NDF content (patch 287) and full RxNorm release dated 8/1/2011. TOTAL CONCEPTS IN PREVIOUS VERSION (2011.08.01.11AA): 45625 VA Product concepts added: 34 Generic concepts added: 5 Ingredient concepts added: 7 VA Drug Interaction concepts added: 83 New concepts manually added for current version: 2 TOTAL CONCEPTS IN CURRENT VERSION (2011.09.06.11AA): 45756 The 2 new concepts manually added for this release included 1 added to the PE hierarchy and 1 added to FDA Established Pharmacologic Classes. No concept name changes occurred for this release. ----------------------------------------------------------------- August 2011 NDF-RT (version name 2011.08.01) NDF-RT is now published on the first Monday of each month to coincide with the release date of RxNorm. This will better ensure that RxNorm_CUI and RxNorm_Name property values will remain up-to-date and in sync with monthly RxNorm content. Content in this version of NDF-RT represents refreshed NDF and RxNorm data, comprising the following changes based on June 2011 NDF content (patch 284) and full RxNorm release dated 7/5/2011. TOTAL CONCEPTS IN PREVIOUS VERSION (2011.07.05.11AA): 45523 VA Product concepts added: 28 Generic concepts added: 3 Ingredient concepts added: 12 VA Drug Interaction concepts added: 56 New concepts manually added for current version: 3 TOTAL CONCEPTS IN CURRENT VERSION (2011.08.01.11AA): 45625 The 3 new concepts manually added for this release included 2 added to the MoA hierarchy and 1 added to FDA Established Pharmacologic Classes. No concept name changes occurred for this release. ----------------------------------------------------------------- July 2011 NDF-RT (version name 2011.07.05) NDF-RT is now published on the first Monday of each month to coincide with the release date of RxNorm. This will better ensure that RxNorm_CUI and RxNorm_Name property values will remain up-to-date and in sync with monthly RxNorm content. Content in this version of NDF-RT represents refreshed NDF and RxNorm data, comprising the following changes based on May 2011 NDF content (patch 281) and full RxNorm release dated 6/6/2011. This release also represents an update of the Disease/Finding and Chemical/Ingredient hierarchies based on MeSH Diseases and Chemicals (from the current version of MeSH available in the 2011AA version of the UMLS Metathesaurus): TOTAL CONCEPTS IN PREVIOUS VERSION (2011.06.06.10AB): 45428 VA Product concepts added: 20 Generic concepts added: 2 Ingredient concepts added: 3 VA Drug Interaction concepts added: 62 New Disease/Finding concepts added from MeSH Diseases: 1 MeSH Diseases concepts programmatically removed: 1 New concepts manually added for current version: 8 TOTAL CONCEPTS IN CURRENT VERSION (2011.07.05.11AA): 45523 The 8 new concepts manually added for this release included 4 added to the MoA hierarchy and 4 added to FDA Established Pharmacologic Classes. In addition, the following concept name changes occurred for this release: External Pharmacologic Classes was changed to FDA Established Pharmacologic Classes, and Pediculocide [EPC] was changed to Pediculicide [EPC]. ----------------------------------------------------------------- June 2011 NDF-RT (version name 2011.06.06) NDF-RT is now published on the first Monday of each month to coincide with the release date of RxNorm. This will better ensure that RxNorm_CUI and RxNorm_Name property values will remain up-to-date and in sync with monthly RxNorm content. Content in this version of NDF-RT represents refreshed NDF and RxNorm data, comprising the following changes based on April 2011 NDF content (patch 278) and full RxNorm release dated 5/2/2011. TOTAL CONCEPTS IN PREVIOUS VERSION (2011.05.02.10AB): 45362 VA Product concepts added: 30 Ingredient concepts added: 3 VA Drug Interaction concepts added: 33 TOTAL CONCEPTS IN CURRENT VERSION (2011.06.06.10AB): 45428 No concept name changes occurred for this release. ----------------------------------------------------------------- May 2011 NDF-RT (version name 2011.05.02) NDF-RT is now published on the first Monday of each month to coincide with the release date of RxNorm. This will better ensure that RxNorm_CUI and RxNorm_Name property values will remain up-to-date and in sync with monthly RxNorm content. Content in this version of NDF-RT represents refreshed NDF and RxNorm data, comprising the following changes based on March 2011 NDF content (patch 275) and full RxNorm release dated 4/4/2011. TOTAL CONCEPTS IN PREVIOUS VERSION (2011.04.04.10AB): 45235 VA Product concepts added: 37 Generic concepts added: 6 Ingredient concepts added: 8 VA Drug Interaction concepts added: 76 TOTAL CONCEPTS IN CURRENT VERSION (2011.05.02.10AB): 45362 No concept name changes occurred for this release. ----------------------------------------------------------------- April 2011 NDF-RT (version name 2011.04.04) NDF-RT will now be published on the first Monday of each month to coincide with the release date of RxNorm. This will better ensure that RxNorm_CUI and RxNorm_Name property values will remain up-to-date and in sync with monthly RxNorm content. Content in this version of NDF-RT represents refreshed NDF and RxNorm data, comprising the following changes based on February 2011 NDF content (patch 272) and full RxNorm release dated 3/7/2011. TOTAL CONCEPTS IN PREVIOUS VERSION (2011.03.07.10AB): 45197 VA Product concepts added: 19 Ingredient concepts added: 1 VA Drug Interaction concepts added: 18 TOTAL CONCEPTS IN CURRENT VERSION (2011.04.04.10AB): 45235 No concept name changes occurred for this release. ----------------------------------------------------------------- March 2011 NDF-RT (version name 2011.03.07) NDF-RT will now be published on the first Monday of each month to coincide with the release date of RxNorm. This will better ensure that RxNorm_CUI and RxNorm_Name property values will remain up-to-date and in sync with monthly RxNorm content. Content in this version of NDF-RT represents refreshed NDF and RxNorm data, comprising the following changes based on January 2011 NDF content (patch 269) and full RxNorm release dated 2/7/2011. TOTAL CONCEPTS IN PREVIOUS VERSION (2011.02.07.10AB): 45149 VA Product concepts added: 9 Generic concepts added: 1 Ingredient concepts added: 1 VA Drug Interaction concepts added: 37 TOTAL CONCEPTS IN CURRENT VERSION (2011.03.07.10AB): 45197 No concept name changes occurred for this release. ----------------------------------------------------------------- February 2011 NDF-RT (version name 2011.02.07) NDF-RT will now be published on the first Monday of each month to coincide with the release date of RxNorm. This will better ensure that RxNorm_CUI and RxNorm_Name property values will remain up-to-date and in sync with monthly RxNorm content. Content in this version of NDF-RT represents refreshed NDF and RxNorm data, comprising the following changes based on December 2010 NDF content (patch 266) and full RxNorm release dated 1/3/2011. This release also represents a refresh of the Disease/Finding hierarchy based on MeSH Diseases (from the current version of MeSH available in the 2010AB version of the UMLS Metathesaurus): TOTAL CONCEPTS IN PREVIOUS VERSION (2011.01.03.10AB): 44936 VA Product concepts added: 28 Generic concepts added: 7 Ingredient concepts added: 7 VA Drug Interaction concepts added: 58 New Disease/Finding concepts added from MeSH Diseases: 92 MeSH Diseases concepts programmatically removed: 4 New concepts manually added for current version: 25 TOTAL CONCEPTS IN CURRENT VERSION (2011.02.07.10AB): 45149 The 25 new concepts manually added for this release included 13 added to the MoA hierarchy, 7 added to the PE hierarchy, and 5 added to External Pharmacologic Classes. In addition, the following concept name changes occurred for this release: Carbohydrate-Deficient Glycoprotein Syndrome [Disease/Finding] was changed to Congenital Disorders of Glycosylation [Disease/Finding], Cryopyrin-associated Periodic Syndromes [Disease/Finding] was changed to Cryopyrin-Associated Periodic Syndromes [Disease/Finding], Estrogen Receptor Inhibitor [EPC] was changed to Estrogen Receptor Antagonist [EPC], Hermaphroditism, True [Disease/Finding] was changed to Ovotesticular Disorders of Sex Development [Disease/Finding], Listeria Infections [Disease/Finding] was changed to Listeriosis [Disease/Finding], Ovarian Failure, Premature [Disease/Finding] was changed to Primary Ovarian Insufficiency [Disease/Finding], Paget Disease Extramammary [Disease/Finding] was changed to Paget Disease, Extramammary [Disease/Finding], and Sex Differentiation Disorders [Disease/Finding] was changed to Disorders of Sex Development [Disease/Finding]. ----------------------------------------------------------------- December 2010/January 2011 NDF-RT (version name 2011.01.03) NDF-RT will now be published on the first Monday of each month to coincide with the release date of RxNorm. This will better ensure that RxNorm_CUI and RxNorm_Name property values will remain up-to-date and in sync with monthly RxNorm content. Content in this version of NDF-RT represents refreshed NDF and RxNorm data, comprising the following changes based on November 2010 NDF content (patch 256) and full RxNorm release dated 12/6/2010. This release also represents a refresh of the Chemical/Ingredient hierarchy based on MeSH Chemicals (from the current version of MeSH available in the 2010AB version of the UMLS Metathesaurus): TOTAL CONCEPTS IN PREVIOUS VERSION (2010.11.01.10AA): 44620 VA Product concepts added: 57 Generic concepts added: 5 Ingredient concepts added: 17 VA Drug Interaction concepts added: 141 New Chemical/Ingredient concepts added from MeSH Chemicals: 93 MeSH Chemicals concepts programmatically removed: 8 New concepts manually added for current version: 11 TOTAL CONCEPTS IN CURRENT VERSION (2011.01.03.10AB): 44936 The 11 new concepts manually added for this release included 8 added to the MoA hierarchy and 3 added to External Pharmacologic Classes. In addition, the following concept name changes occurred for this release: 1-Phosphatidylinositol 3-Kinase [Chemical/Ingredient] was changed to Phosphatidylinositol 3-Kinase [Chemical/Ingredient], 2-phenylbenzimidazole-5- sulfonic acid [Chemical/Ingredient] was changed to ensulizole [Chemical/Ingredient], Amyloid beta-Protein [Chemical/Ingredient] was changed to Amyloid beta-Peptides [Chemical/Ingredient], Antibodies, Monoclonal, Murine-derived [Chemical/Ingredient] was changed to Antibodies, Monoclonal, Murine-Derived [Chemical/Ingredient], Antigens, CD26 [Chemical/Ingredient] was changed to Dipeptidyl Peptidase 4 [Chemical/Ingredient], Antithrombins [Chemical/Ingredient] was changed to Antithrombin Proteins [Chemical/Ingredient], Botulinum Toxin Type A [Chemical/Ingredient] was changed to Botulinum Toxins, Type A [Chemical/Ingredient], botulinum toxin type B [Chemical/Ingredient] was changed to rimabotulinumtoxinB [Chemical/Ingredient], Carboxymethylcellulose [Chemical/Ingredient] was changed to Carboxymethylcellulose Sodium [Chemical/Ingredient], Chloroguanide [Chemical/Ingredient] was changed to Proguanil [Chemical/Ingredient], Midodrine Monohydrochloride [Chemical/Ingredient] was changed to Midodrine Hydrochloride [Chemical/Ingredient], Nectar [Chemical/Ingredient] was changed to Plant Nectar [Chemical/Ingredient], Orciprenaline [Chemical/Ingredient] was changed to Metaproterenol [Chemical/Ingredient], Procetofen [Chemical/Ingredient] was changed to Fenofibrate [Chemical/Ingredient], Proteochondroitin Sulfates [Chemical/Ingredient] was changed to Chondroitin Sulfate Proteoglycans [Chemical/Ingredient], silochrome [Chemical/Ingredient] was changed to Silochrome [Chemical/Ingredient], Testosterone 5-alpha- Reductase [Chemical/Ingredient] was changed to 3-Oxo-5-alpha-Steroid 4-Dehydrogenase [Chemical/Ingredient], Thiopronine [Chemical/Ingredient] was changed to Tiopronin [Chemical/Ingredient], Thyroid Extract, Desiccated [Chemical/Ingredient] was changed to Thyroid (USP) [Chemical/Ingredient], Toothpaste [Chemical/Ingredient] was changed to Toothpastes [Chemical/Ingredient], and Triethylenetetramine [Chemical/Ingredient] was changed to Trientine [Chemical/Ingredient]. ----------------------------------------------------------------- November 2010 NDF-RT (version name 2010.11.01) NDF-RT will now be published on the first Monday of each month to coincide with the release date of RxNorm. This will better ensure that RxNorm_CUI and RxNorm_Name property values will remain up-to-date and in sync with monthly RxNorm content. Content in this version of NDF-RT represents refreshed NDF and RxNorm data, comprising the following changes based on October 2010 NDF content (patch 253) and full RxNorm release dated 10/4/2010: TOTAL CONCEPTS IN PREVIOUS VERSION (2010.10.04.10AA): 44462 VA Product concepts added: 94 Generic concepts added: 11 Ingredient concepts added: 15 VA Drug Interaction concepts added: 38 TOTAL CONCEPTS IN CURRENT VERSION (2010.11.01.10AA): 44620 No concept name changes occurred for this release. ----------------------------------------------------------------- October 2010 NDF-RT (version name 2010.10.04) NDF-RT will now be published on the first Monday of each month to coincide with the release date of RxNorm. This will better ensure that RxNorm_CUI and RxNorm_Name property values will remain up-to-date and in sync with monthly RxNorm content. Content in this version of NDF-RT represents refreshed NDF and RxNorm data, comprising the following changes based on September 2010 NDF content (patch 250) and full RxNorm release dated 9/7/2010: TOTAL CONCEPTS IN PREVIOUS VERSION (2010.09.07.10AA): 44337 VA Product concepts added: 27 Generic concepts added: 4 Ingredient concepts added: 3 VA Drug Interaction concepts added: 91 TOTAL CONCEPTS IN CURRENT VERSION (2010.10.04.10AA): 44462 No concept name changes occurred for this release. ----------------------------------------------------------------- September 2010 NDF-RT (version name 2010.09.07) NDF-RT will now be published on the first Monday of each month to coincide with the release date of RxNorm. This will better ensure that RxNorm_CUI and RxNorm_Name property values will remain up-to-date and in sync with monthly RxNorm content. Content in this version of NDF-RT represents refreshed NDF and RxNorm data, comprising the following changes based on August 2010 NDF content (patch 247) and full RxNorm release dated 8/2/2010. This release also represents a refresh of the Disease/Finding hierarchy based on MeSH Diseases (from the current version of MeSH available in the 2010AA version of the UMLS Metathesaurus): TOTAL CONCEPTS IN PREVIOUS VERSION (2010.08.02.10AA): 43855 VA Product concepts added: 50 Generic concepts added: 3 Ingredient concepts added: 7 VA Drug Interaction concepts added: 164 New Disease/Finding concepts added from MeSH Diseases refresh: 294 MeSH Diseases concepts programmatically removed: 48 New concepts manually added for current version: 12 TOTAL CONCEPTS IN CURRENT VERSION (2010.09.07.10AA): 44337 The 12 concepts manually added for this version included were all added to the MoA hierarchy. There were also a number of manual name changes made for this release: Absorbs Ultraviolet A Radiation [MoA] was changed to Ultraviolet A Radiation Absorption [MoA], Absorbs Ultraviolet B Radiation [MoA] was changed to Ultraviolet A Radiation Absorption [MoA], Adjuvants, Immunologic [MoA] was changed to Immunologic Adjuvants [MoA], Age categories [Disease/Finding] was changed to Age Categories [Disease/Finding], Antithrombin III Activators [MoA] was changed to Antithrombin 3 Activators [MoA], beta Tubulin Interaction [MoA] was changed to beta Tubulin Interactions [MoA], Bone Surface Interaction [MoA] was changed to Bone Surface Interactions [MoA], COX-2 Inhibitors [MoA] was changed to Cyclooxygenase 2 Inhibitors [MoA], Current Non-Smoker [Disease/Finding] was changed to Current Non-smoker [Disease/Finding], Decreased Calcium-Sensing Receptor Sensitivity [MoA] was changed to Decreased Calcium-sensing Receptor Sensitivity [MoA], Elderly adult [Disease/Finding] was changed to Elderly Adult [Disease/Finding], Female gender [Disease/Finding] was changed to Female Gender [Disease/Finding], Free Radical Scavenging [MoA] was changed to Free Radical Scavenging Activity [MoA], Glucagon Receptor Interaction [MoA] was changed to Glucagon Receptor Interactions [MoA], Histamine Antagonists [MoA] was changed to Histamine Receptor Antagonists [MoA], Histamine H1 Antagonists [MoA] was changed to Histamine H1 Receptor Antagonists [MoA], Histamine H2 Antagonists [MoA] was changed to Histamine H2 Receptor Antagonists [MoA], Increased Calcium-Sensing Receptor Sensitivity [MoA] was changed to Increased Calcium-sensing Receptor Sensitivity [MoA], Male gender [Disease/Finding] was changed to Male Gender [Disease/Finding], Middle aged adult [Disease/Finding] was changed to Middle Aged Adult [Disease/Finding], Older child [Disease/Finding] was changed to Older Child [Disease/Finding], Peroxisome Proliferator-Activated Receptor Activity [MoA] was changed to Peroxisome Proliferator-activated Receptor Activity [MoA], Peroxisome Proliferator-Activated Receptor alpha Agonists [MoA] was changed to Peroxisome Proliferator-activated Receptor alpha Agonists [MoA], Peroxisome Proliferator-Activated Receptor beta Agonists [MoA] was changed to Peroxisome Proliferator-activated Receptor beta Agonists [MoA], Peroxisome Proliferator-Activated Receptor delta Agonists [MoA] was changed to Peroxisome Proliferator-activated Receptor delta Agonists [MoA], Peroxisome Proliferator-Activated Receptor gamma Agonists [MoA] was changed to Peroxisome Proliferator-activated Receptor gamma Agonists [MoA], Platelet-Derived Growth Factor alpha Receptor Inhibitors [MoA] was changed to Platelet-derived Growth Factor alpha Receptor Inhibitors [MoA], Platelet-Derived Growth Factor alpha Receptor Interactions [MoA] was changed to Platelet-derived Growth Factor alpha Receptor Interactions [MoA], Platelet-Derived Growth Factor beta Receptor Inhibitors [MoA] was changed to Platelet-derived Growth Factor beta Receptor Inhibitors [MoA], Platelet-Derived Growth Factor beta Receptor Interactions [MoA] was changed to Platelet-derived Growth Factor beta Receptor Interactions [MoA], Platelet-Derived Growth Factor Receptor Inhibitors [MoA] was changed to Platelet-derived Growth Factor Receptor Inhibitors [MoA], Preterm infant [Disease/Finding] was changed to Preterm Infant [Disease/Finding], Receptor Activity Modifying Proteins Antagonists [MoA] was changed to Receptor Activity Modifying Protein Antagonists, Tubulin Interaction [MoA] was changed to Tubulin Interactions [MoA], Tumor Necrosis Factor Alpha Receptor Blocking Activity [MoA] was changed to Tumor Necrosis Factor alpha Receptor Blocking Activity [MoA], Tumor Necrosis Factor Beta Receptor Blocking Activity [MoA] was changed to Tumor Necrosis Factor beta Receptor Blocking Activity, Viral Envelope Interaction [MoA] was changed to Viral Envelope Interactions [MoA], Young adult [Disease/Finding] was changed to Young Adult [Disease/Finding], and Young child [Disease/Finding] was changed to Young Child [Disease/Finding]. ----------------------------------------------------------------- August 2010 NDF-RT (version name 2010.08.02) NDF-RT will now be published on the first Monday of each month to coincide with the release date of RxNorm. This will better ensure that RxNorm_CUI and RxNorm_Name property values will remain up-to-date and in sync with monthly RxNorm content. Content in this version of NDF-RT represents refreshed NDF and RxNorm data, comprising the following changes based on July 2010 NDF content (patch 244) and full RxNorm release dated 7/6/2010: TOTAL CONCEPTS IN PREVIOUS VERSION (2010.07.06.10AA): 43816 VA Product concepts added: 12 Generic concepts added: 2 Ingredient concepts added: 2 VA Drug Interaction concepts added: 23 TOTAL CONCEPTS IN CURRENT VERSION (2010.08.02.10AA): 43855 No concept name changes occurred for this release. ----------------------------------------------------------------- July 2010 NDF-RT (version name 2010.07.06) NDF-RT will now be published on the first Monday of each month to coincide with the release date of RxNorm. This will better ensure that RxNorm_CUI and RxNorm_Name property values will remain up-to-date and in sync with monthly RxNorm content. Content in this version of NDF-RT represents refreshed NDF and RxNorm data, comprising the following changes based on June 2010 NDF content (patch 241) and full RxNorm release dated 6/7/2010: TOTAL CONCEPTS IN PREVIOUS VERSION (2010.06.07.10AA): 43789 VA Product concepts added: 18 Generic concepts added: 3 Ingredient concepts added: 5 VA Drug Interaction concepts added: 1 TOTAL CONCEPTS IN CURRENT VERSION (2010.07.06.10AA): 43816 There were 4 manual concept name changes this month: Autonomic Ganglionic Blockers [EPC] was changed to Autonomic Ganglionic Blocker [EPC], Electrolytes [EPC] was changed to Electrolyte [EPC], Human Immunodeficiency Virus 1 Non-Nucleoside and Nucleoside Analog Reverse Transcriptase Inhibitors [EPC] was changed to Human Immunodeficiency Virus 1 Non-Nucleoside and Nucleoside Analog Reverse Transcriptase Inhibitor [EPC], and Locally acting Aminosalicylate [EPC] was changed to Locally-acting Aminosalicylate [EPC]. ----------------------------------------------------------------- June 2010 NDF-RT (version name 2010.06.07) NDF-RT will now be published on the first Monday of each month to coincide with the release date of RxNorm. This will better ensure that RxNorm_CUI and RxNorm_Name property values will remain up-to-date and in sync with monthly RxNorm content. Content in this version of NDF-RT represents refreshed NDF and RxNorm data, comprising the following changes based on May 2010 NDF content (patch 238) and full RxNorm release dated 5/3/2010: TOTAL CONCEPTS IN PREVIOUS VERSION (2010.04.13.9AB): 43706 VA Product concepts added: 18 Generic concepts added: 3 Ingredient concepts added: 4 VA Drug Interaction concepts added: 51 New concepts manually added for current version: 7 TOTAL CONCEPTS IN CURRENT VERSION (2010.06.07.10AA): 43789 The 7 concepts manually added for this version included were all added to External Pharmacologic Classes. There were also 2 manual concept name changes this month: Insulin Analogue [EPC] was changed to Insulin Analog [EPC], and Prostaglandin Analogue [EPC] was changed to Prostaglandin Analog [EPC]. Other concept name changes were derived programmatically from this month's refreshed MeSH Chemicals content. ----------------------------------------------------------------- April 2010 NDF-RT (version name 2010.04.13) This release reflects content in a new NDF-RT namespace, which is intended to be the "next generation" of NDF-RT, comprising a multi-namespace approach that will restore focus on orderable clinical drugs, ingredients, and descriptive classifications. It will also support clinical decision support, quality of care research, and FDA SPL drug labeling initiatives. For more information, please refer to the release notes from the December 2008/January 2009 version (2009.01.13, below), as well as the document Changes in NDF-RT Public Edition.pdf, included with these release files. Content in this version of NDF-RT represents refreshed NDF and RxNorm data, comprising the following changes based on April 2010 NDF content (patch 235) and full RxNorm release dated 4/5/2010: TOTAL CONCEPTS IN PREVIOUS VERSION (2010.03.09.9AB): 43483 VA Product concepts added: 20 Generic concepts added: 1 Ingredient concepts added: 5 VA Drug Interaction concepts added: 197 TOTAL CONCEPTS IN CURRENT VERSION (2010.04.13.9AB): 43706 No concept name changes occurred for this release. ----------------------------------------------------------------- March 2010 NDF-RT (version name 2010.03.09) This release reflects content in a new NDF-RT namespace, which is intended to be the "next generation" of NDF-RT, comprising a multi-namespace approach that will restore focus on orderable clinical drugs, ingredients, and descriptive classifications. It will also support clinical decision support, quality of care research, and FDA SPL drug labeling initiatives. For more information, please refer to the release notes from the December 2008/January 2009 version (2009.01.13, below), as well as the document Changes in NDF-RT Public Edition.pdf, included with these release files. Content in this version of NDF-RT represents refreshed NDF and RxNorm data, comprising the following changes based on March 2010 NDF content (patch 232) and full RxNorm release dated 3/1/2010: TOTAL CONCEPTS IN PREVIOUS VERSION (2010.02.09.9AB): 43414 VA Product concepts added: 29 Generic concepts added: 3 Ingredient concepts added: 2 VA Drug Interaction concepts added: 35 TOTAL CONCEPTS IN CURRENT VERSION (2010.03.09.9AB): 43483 There were two manual concept name changes for this release: E3 Ubiquitin Ligase Inhibitor [MoA] was changed to E3 Ubiquitin Ligase Inhibitors [MoA], and Para-Aminobenzoic Acid Inhibitor [MoA] was changed to Para-Aminobenzoic Acid Inhibitors [MoA]. ----------------------------------------------------------------- February 2010 NDF-RT (version name 2010.02.09) This release reflects content in a new NDF-RT namespace, which is intended to be the "next generation" of NDF-RT, comprising a multi-namespace approach that will restore focus on orderable clinical drugs, ingredients, and descriptive classifications. It will also support clinical decision support, quality of care research, and FDA SPL drug labeling initiatives. For more information, please refer to the release notes from the December 2008/January 2009 version (2009.01.13, below), as well as the document Changes in NDF-RT Public Edition.pdf, included with these release files. Content in this version of NDF-RT represents refreshed NDF and RxNorm data, comprising the following changes based on February 2010 NDF content (patch 228) and full RxNorm release dated 2/1/2010: TOTAL CONCEPTS IN PREVIOUS VERSION (2010.01.12.9AB): 43285 VA Product concepts added: 11 Generic concepts added: 1 Ingredient concepts added: 1 VA Drug Interaction concepts added: 116 TOTAL CONCEPTS IN CURRENT VERSION (2010.02.09.9AB): 43414 One manual concept name change occurred this month. L-Calcium Channel Receptor Antagonists[MoA] was changed to L-Calcium Channel Receptor ----------------------------------------------------------------- December 2009/January 2010 NDF-RT (version name 2010.01.12) This release reflects content in a new NDF-RT namespace, which is intended to be the "next generation" of NDF-RT, comprising a multi-namespace approach that will restore focus on orderable clinical drugs, ingredients, and descriptive classifications. It will also support clinical decision support, quality of care research, and FDA SPL drug labeling initiatives. For more information, please refer to the release notes from the December 2008/January 2009 version (2009.01.13, below), as well as the document Changes in NDF-RT Public Edition.pdf, included with these release files. Content in this version of NDF-RT represents refreshed NDF and RxNorm data, comprising the following changes based on January 2010 NDF content (patch 225) and full RxNorm release dated 1/4/2010: 43,147 TOTAL CONCEPTS IN PREVIOUS VERSION (2009.11.10.9AB) 67 VA Product concepts added 4 Generic concepts added 19 Ingredient concepts added 45 VA Drug Interaction concepts added 3 New concepts manually added for current version 43,285 TOTAL CONCEPTS IN CURRENT VERSION (2010.01.12.9AB) The 3 concepts manually added for this version included were all added to External Pharmacologic Classes. A number of manual concept name changes also occurred this month, fixing pluralization and capitalization inconsistencies: 14-alpha demethylase Inhibitors [MoA] was changed to 14-alpha Demethylase Inhibitors [MoA], ADH Receptor Antagonist [MoA] was changed to ADH Receptor Antagonists [MoA], AMPA Receptor Antagonist [MoA] was changed to AMPA Receptor Antagonists [MoA], Amylin Agonist [MoA] was changed to Amylin Agonists [MoA], Antidiuretic Hormone Antagonist [MoA] was changed to Antidiuretic Hormone Antagonists [MoA], Catecholamine-depleting Sympatholytics [EPC] was changed to Catecholamine-depleting Sympatholytic [EPC], decreased fibroblast migration [PE] was changed to Decreased Fibroblast Migration [PE], decreased polymorphonuclear leukocyte migration [PE] was changed to Decreased Polymorphonuclear Leukocyte Migration [PE], Glucagon-like Peptide-1 (GLP-1) Agonist [MoA] was changed to Glucagon-like Peptide-1 (GLP-1) Agonists [MoA], Glucagon-like Peptide-1 (GLP-1) Antagonist [MoA] was changed to Glucagon-like Peptide-1 (GLP-1) Antagonists [MoA], Hypothalamic Hormone Receptor Agonist [MoA] was changed to Hypothalamic Hormone Receptor Agonists [MoA], Hypothalamic Hormone Receptor Antagonist [MoA] was changed to Hypothalamic Hormone Receptor Antagonists [MoA], increased fibroblast migration [PE] was changed to Increased Fibroblast Migration [PE], Increased polymorphonuclear leukocyte migration [PE] was changed to Increased Polymorphonuclear Leukocyte Migration [PE], increased Urethra Smooth Muscle Tone [PE] was changed to Increased Urethra Smooth Muscle Tone [PE], Inhalation Diagnostic Agents [EPC] was changed to Inhalation Diagnostic Agent [EPC], Ionotropic Glutamate Receptor Antagonist [MoA] was changed to Ionotropic Glutamate Receptor Antagonists [MoA], Kainate Receptor Antagonist [MoA] was changed to Kainate Receptor Antagonists [MoA], Keratinocyte Growth Factor Receptor Agonist [MoA] was changed to Keratinocyte Growth Factor Receptor Agonists [MoA], Keratinocyte Growth Factor Receptor Antagonist [MoA] was changed to Keratinocyte Growth Factor Receptor Antagonists [MoA], L-Calcium Channel Receptor Antagonist [MoA] was changed to L-Calcium Channel Receptor Antagonists[MoA], N-Calcium Channel Receptor Antagonist [MoA] was changed to N-Calcium Channel Receptor Antagonists [MoA], Receptor Activity Modifying Protein Agonist [MoA] was changed to Receptor Activity Modifying Protein Agonists [MoA], Receptor Activity Modifying Proteins Antagonist [MoA] was changed to Receptor Activity Modifying Proteins Antagonists [MoA], T-Calcium Channel Receptor Antagonist [MoA] was changed to T-Calcium Channel Receptor Antagonists [MoA], and Voltage-gated Calcium Channel Receptor Antagonist [MoA] was changed to Voltage-gated Calcium Channel Receptor Antagonists [MoA]. ----------------------------------------------------------------- November 2009 NDF-RT (version name 2009.11.10) This release reflects content in a new NDF-RT namespace, which is intended to be the "next generation" of NDF-RT, comprising a multi-namespace approach that will restore focus on orderable clinical drugs, ingredients, and descriptive classifications. It will also support clinical decision support, quality of care research, and FDA SPL drug labeling initiatives. For more information, please refer to the release notes from the December 2008/January 2009 version (2009.01.13, below), as well as the document Changes in NDF-RT Public Edition.pdf, included with these release files. Content in this version of NDF-RT represents refreshed RxNorm, UMLS CUI, and MeSH Chemicals data, comprising the following changes based on the full RxNorm release dated 11/2/2009, and MeSH/UMLS CUI content extracted from UMLS version 2009AB (released in November 2009): 43,050 TOTAL CONCEPTS IN PREVIOUS VERSION (2009.10.13.9AA) 98 MeSH Chemicals concepts added 10 New concepts manually added for current version 7 MeSH Chemicals concepts programmatically removed 4 Concepts manually removed for current version 43,147 TOTAL CONCEPTS IN CURRENT VERSION (2009.11.10.9AB) The 10 concepts manually added for this version included 10 added to External Pharmacologic Classes. Several manual concept name changes also occurred this month: M2 Proton Pump Inhibitor [EPC] was changed to Influenza A M2 Protein Inhibitor [EPC], and Melanocyte Pigment Inhibitor [EPC] was changed to Melanin Synthesis Inhibitor [EPC]. Other concept name changes were derived programmatically from this month's refreshed MeSH Chemicals content. ----------------------------------------------------------------- October 2009 NDF-RT (version name 2009.10.13) This release reflects content in a new NDF-RT namespace, which is intended to be the "next generation" of NDF-RT, comprising a multi-namespace approach that will restore focus on orderable clinical drugs, ingredients, and descriptive classifications. It will also support clinical decision support, quality of care research, and FDA SPL drug labeling initiatives. For more information, please refer to the release notes from the December 2008/January 2009 version (2009.01.13, below), as well as the document Changes in NDF-RT Public Edition.pdf, included with these release files. Content in this version of NDF-RT represents refreshed NDF, RxNorm, and UMLS CUI data, comprising the following changes based on October 2009 NDF content (patch 216), full RxNorm release dated 10/5/2009, and UMLS CUI content extracted from UMLS version 2009AA (released in April 2009): 42,671 TOTAL CONCEPTS IN PREVIOUS VERSION (2009.09.08.9AA) 96 VA Product concepts added 8 Generic concepts added 25 Ingredient concepts added 250 VA Drug Interaction concepts added 43,050 TOTAL CONCEPTS IN CURRENT VERSION (2009.10.13.9AA) Concept name changes in this version were derived programmatically from this month's refreshed NDF content. ----------------------------------------------------------------- August/September 2009 NDF-RT (version name 2009.09.08) This release reflects content in a new NDF-RT namespace, which is intended to be the "next generation" of NDF-RT, comprising a multi-namespace approach that will restore focus on orderable clinical drugs, ingredients, and descriptive classifications. It will also support clinical decision support, quality of care research, and FDA SPL drug labeling initiatives. For more information, please refer to the release notes from the December 2008/January 2009 version (2009.01.13, below), as well as the document Changes in NDF-RT Public Edition.pdf, included with these release files. Content in this version of NDF-RT represents refreshed NDF, RxNorm, and MeSH Chemicals data, comprising the following changes based on August 2009 NDF content (patch 210), full RxNorm release dated 9/8/2009, and MeSH content extracted from UMLS version 2009AA (released in April 2009): 41,363 TOTAL CONCEPTS IN PREVIOUS VERSION (2009.07.14.9AA) 39 VA Product concepts added 8 Generic concepts added 19 Ingredient concepts added 11 VA Drug Interaction concepts added 1 RxNorm Dose Form concepts added 1,244 MeSH Chemicals concepts added 4 New concepts manually added for current version 16 MeSH Chemicals concepts programmatically removed 2 Concepts manually removed for current version 42,671 TOTAL CONCEPTS IN CURRENT VERSION (2009.09.08.9AA) The 4 concepts manually added for this version included 3 added to the PE hierarchy, and 1 added to External Pharmacologic Classes. For this version, all concepts under External Pharmacologic Classes (totaling 409), formerly containing the tag [EXT] appended to the concept name, have been changed by replacing the [EXT] tag with [EPC]. Other concept name changes were derived programmatically from this month's refreshed MeSH and NDF content. ----------------------------------------------------------------- July 2009 NDF-RT (version name 2009.07.14) This release reflects content in a new NDF-RT namespace, which is intended to be the "next generation" of NDF-RT, comprising a multi-namespace approach that will restore focus on orderable clinical drugs, ingredients, and descriptive classifications. It will also support clinical decision support, quality of care research, and FDA SPL drug labeling initiatives. For more information, please refer to the release notes from the December 2008/January 2009 version (2009.01.13, below), as well as the document Changes in NDF-RT Public Edition.pdf, included with these release files. Content in this version of NDF-RT represents refreshed NDF and RxNorm data, comprising the following changes based on July 2009 NDF content (patch 207) and full RxNorm release dated 7/6/2009: 41,299 TOTAL CONCEPTS IN PREVIOUS VERSION (2009.06.09.9AA) 50 VA Product concepts added 5 Generic concepts added 9 Ingredient concepts added 41,363 TOTAL CONCEPTS IN CURRENT VERSION (2009.07.14.9AA) There were 2 concept name changes this month: HYDROMORPHONE 0.2MG/ML INJ,30ML [VA Product] was changed to HYDROMORPHONE HCL 0.2MG/ML INJ,30ML [VA Product], and MYCOPHENOLATE MOFETIL HYDROCHLORIDE 500MG/VIL INJ,IV [VA Product] was changed to MYCOPHENOLATE MOFETIL HYDROCHLORIDE 500MG/VIL INJ [VA Product]. ----------------------------------------------------------------- June 2009 NDF-RT (version name 2009.06.09) This release reflects content in a new NDF-RT namespace, which is intended to be the "next generation" of NDF-RT, comprising a multi-namespace approach that will restore focus on orderable clinical drugs, ingredients, and descriptive classifications. It will also support clinical decision support, quality of care research, and FDA SPL drug labeling initiatives. For more information, please refer to the release notes from the December 2008/January 2009 version (2009.01.13, below), as well as the document Changes in NDF-RT Public Edition.pdf, included with these release files. Content in this version of NDF-RT represents refreshed NDF and RxNorm data, comprising the following changes based on May 2009 NDF content (patch 204) and full RxNorm release dated 6/1/2009: 41,255 TOTAL CONCEPTS IN PREVIOUS VERSION (2009.05.12.9AA) 21 VA Product concepts added 2 VA Drug Interaction concepts added 2 Generic concepts added 3 Ingredient concepts added 5 RxNorm Dose Form concepts added 11 New concepts manually added for current version 41,299 TOTAL CONCEPTS IN CURRENT VERSION (2009.06.09.9AA) There were 27 concept name changes this month. All concepts in the Therapeutic Uses [Therapeutic Intent] hierarchy, added for the May release, were renamed, with [TC] replacing the former [Therapeutic Intent] tag appended to each concept name. The top-level concept in this hierarchy, Therapeutic Uses [Therapeutic Intent], was renamed to Therapeutic Categories [TC]. Any concepts in NDF-RT with a role pointing to a concept in this hierarchy will now show the name of this role as "has_TC", replacing the former "has_Therapeutic_Intent". The 11 new concepts manually added for this release included 1 added to the MoA hierarchy, 7 added to the EXT hierarchy, and 3 added to the new Therapeutic Categories [TC] hierarchy. ----------------------------------------------------------------- May 2009 NDF-RT (version name 2009.05.12) This release reflects content in a new NDF-RT namespace, which is intended to be the "next generation" of NDF-RT, comprising a multi-namespace approach that will restore focus on orderable clinical drugs, ingredients, and descriptive classifications. It will also support clinical decision support, quality of care research, and FDA SPL drug labeling initiatives. For more information, please refer to the release notes from the December 2008/January 2009 version (2009.01.13, below), as well as the document Changes in NDF-RT Public Edition.pdf, included with these release files. Content in this version of NDF-RT represents refreshed NDF and RxNorm data, comprising the following changes based on April 2009 NDF content (patch 201) and full RxNorm release dated 5/4/2009: 41,180 TOTAL CONCEPTS IN PREVIOUS VERSION (2009.04.14.9AA) 24 VA Product concepts added 4 VA Drug Interaction concepts added 2 Generic concepts added 4 Ingredient concepts added 41 New concepts manually added for current version 41,255 TOTAL CONCEPTS IN CURRENT VERSION (2009.04.14.9AA) The 41 new concepts manually added for this release include the creation of the new Therapeutic Uses [Therapeutic Intent] hierarchy. Concepts in this hierarchy were added to provide has_Therapeutic_Intent mappings to a number of EXT concepts containing therapeutic intent components. In addition to the 27 concepts in this hierarchy, manually added concepts for this month included 2 added to the MoA hierarchy, 9 added to the PE hierarchy, 2 added to the Chemical/Ingredient hierarchy, and 1 added to the EXT hierarchy. There were 3 concept name changes this month: perflexane [Chemical/Ingredient] was changed to perfluorohexane [Chemical/Ingredient]; Vascular Endothelial Growth Factor Receptor-directed Antibody Interactions [MoA] was changed to Vascular Endothelial Growth Factor-directed Antibody Interactions [MoA]; and Vascular Endothelial Growth Factor Receptor-directed Antibody [EXT] was changed to Vascular Endothelial Growth Factor-directed Antibody [EXT]. ----------------------------------------------------------------- April 2009 NDF-RT (version name 2009.04.14) This release reflects content in a new NDF-RT namespace, which is intended to be the "next generation" of NDF-RT, comprising a multi-namespace approach that will restore focus on orderable clinical drugs, ingredients, and descriptive classifications. It will also support clinical decision support, quality of care research, and FDA SPL drug labeling initiatives. For more information, please refer to the release notes from the December 2008/January 2009 version (2009.01.13, below), as well as the document Changes in NDF-RT Public Edition.pdf, included with these release files. Content in this version of NDF-RT represents refreshed NDF and RxNorm data, comprising the following changes based on March 2009 NDF content (patch 198) and full RxNorm release dated 4/6/2009: 40,797 TOTAL CONCEPTS IN PREVIOUS VERSION (2009.03.10.8AB) 226 VA Product concepts added 96 VA Drug Interaction concepts added 11 Generic concepts added 40 Ingredient concepts added 2 Drug Class concepts added 9 New concepts manually added for current version 1 Concepts manually removed for this version 41,180 TOTAL CONCEPTS IN CURRENT VERSION (2009.04.14.9AA) The 9 new concepts manually added for this release included 1 added to the MoA hierarchy, 3 added to the Chemical/Ingredient hierarchy, and 5 added to the EXT hierarchy. The changed concepts count this month is due to 6 concept name changes: Folic Acid Antagonists [MoA] was changed to Folic Acid Metabolism Inhibitors [MoA]; Peroxisome Proliferator-Activated Receptor Alpha Activity [MoA] was changed to Peroxisome Proliferator-Activated Receptor alpha Agonists [MoA]; Peroxisome Proliferator-Activated Receptor Beta Activity [MoA] was changed to DPeroxisome Proliferator-Activated Receptor beta Agonists [MoA]; Peroxisome Proliferator-Activated Receptor Delta Activity [MoA] was changed to Peroxisome Proliferator-Activated Receptor delta Agonists [MoA]; Peroxisome Proliferator-Activated Receptor Gamma Activity [MoA] was changed to Peroxisome Proliferator-Activated Receptor gamma Agonists [MoA]; and Peroxisome-proliferator Receptor Alpha Activator [EXT] was changed to Peroxisome Proliferator Receptor alpha Agonist [EXT]. ----------------------------------------------------------------- March 2009 NDF-RT (version name 2009.03.10) This release reflects content in the new namespace, "NDF-RT2 [Public Edition]", which is intended to be the "next generation" of NDF-RT, comprising a multi-namespace approach that will restore focus on orderable clinical drugs, ingredients, and descriptive classifications. It will also support clinical decision support, quality of care research, and FDA SPL drug labeling initiatives. Please note that although this content represents a new namespace, we will continue to refer to this new version as NDF-RT, to reduce consumer confusion. For more information, please refer to the release notes from the December 2008/January 2009 version (2009.01.13, below), as well as the document Changes in NDF-RT v2.0 Public Edition.pdf, included with these release files. Content in this version of NDF-RT represents refreshed NDF and RxNorm data, comprising the following changes based on September 2008 NDF content (patch 179) and full RxNorm release dated 3/2/2009: 39,140 TOTAL CONCEPTS IN PREVIOUS VERSION (2009.02.10.8AB) 1020 VA Product concepts added 613 VA Drug Interaction concepts added 95 Generic concepts added 181 Ingredient concepts added 7 RxNorm Dose Form concepts added 3 Drug Class concepts added 12 New concepts manually added for current version 9 NDF-RT Dose Form concepts added 276 Supply concepts deleted 6 MoA concepts removed for this version 1 PE concepts removed for this version 40,797 TOTAL CONCEPTS IN CURRENT VERSION (2009.03.10.8AB) The 12 new concepts manually added for this release included 3 added to the MoA hierarchy, 6 added to the PE hierarchy, and 3 added to the EXT hierarchy. In addition to the changes noted above, 167 RxNorm Dose Form concepts were programmatically updated for this release during the content refresh. The additional updates comprised changes to 12 MoA concept names during manual reorganization of the MoA hierarchy. ----------------------------------------------------------------- February 2009 NDF-RT (version name 2009.02.10) This release reflects content in the new namespace, "NDF-RT2 [Public Edition]", which is intended to be the "next generation" of NDF-RT, comprising a multi-namespace approach that will restore focus on orderable clinical drugs, ingredients, and descriptive classifications. It will also support clinical decision support, quality of care research, and FDA SPL drug labeling initiatives. Please note that although this content represents a new namespace, we will continue to refer to this new version as NDF-RT, to reduce consumer confusion. For more information, please refer to the release notes from the previous version (2009.01.13, below), as well as the document Changes in NDF-RT v2.0 Public Edition.pdf, included with these release files. This release of NDF-RT Public Edition contains 10 new concepts: 2 added to the EXT hierarchy, 3 added to the MoA hierarchy, and 5 added to the PE hierarchy. 39,140 total concepts 10 new concepts 0 changed concepts 0 concepts removed ----------------------------------------------------------------- December 2008/January 2009 NDF-RT v.2.0 (version name 2009.01.13) This release reflects content in the new namespace, "NDF-RT2 [Public Edition]", which is intended to be the "next generation" of NDF-RT, comprising a multi-namespace approach that will restore focus on orderable clinical drugs, ingredients, and descriptive classifications. It will also support clinical decision support, quality of care research, and FDA SPL drug labeling initiatives. Please note that although this content represents a new namespace, we will continue to refer to this new version as NDF-RT, to reduce consumer confusion. The central content of NDF-RT now consists of core medication reference terminology via NDF and NLM Daily Med updates; salient reference concept hierarchies; and description logic-based drug & ingredient classification. External content derived from other terminology sources will be integrated and maintained via linkages, as opposed to direct incorporation into NDF-RT. "NDF-RT2" was created by removing and reinserting selected concepts and attributes from the November 2008 version of NDF-RT [Public Edition]. Some of the information removed will no longer be maintained, and some will be maintained elsewhere. For example, VA Drug Interaction concepts, previously maintained in NDF-RT and withheld from the NDF-RT Public Edition, were reinserted for and are being included in this new public edition. Orderable supply concepts (those beginning with XA*) and their descendants, NDC-level concepts, and several obsolete VA class concepts were removed. The following list is a summary of the additions and deletions: 136,054 TOTAL CONCEPTS IN PREVIOUS VERSION (2008.11.11.8AA) 95,368 NDC concepts removed 4,525 Orderable supply (members of XA* classes) concepts removed 2 Obsolete drug class concepts removed 2,965 VA Drug Interaction concepts restored 6 New concepts added for current version 39,130 TOTAL CONCEPTS IN CURRENT VERSION (2009.01.13.8AB) The 6 new concepts added to this release include 3 added to the EXT hierarchy, 2 added to the PE hierarchy, and 1 added to the MoA hierarchy. In addition to the removal/restoration of concepts mentioned above, this new version contains a number of changes involving properties and associations, and several corresponding qualifiers. For more information, please refer to the document, Changes in NDF-RT v2.0 Public Edition.pdf, included with these release files. ----------------------------------------------------------------- November 2008 NDF-RT (version name 2008.11.11) This release of NDF-RT Public Edition contains 3 new concepts: 2 added to the EXT hierarchy, and 1 added to the MoA hierarchy. 136,054 total concepts 3 new concepts 0 changed concepts 0 concepts removed ----------------------------------------------------------------- October 2008 NDF-RT (version name 2008.10.14) This release of NDF-RT Public Edition contains no changes from the previous version. 136,051 total concepts 0 new concepts 0 changed concepts 0 concepts removed ----------------------------------------------------------------- August/September 2008 NDF-RT (version name 2008.09.09) This release of NDF-RT Public Edition contains 69 new concepts: 51 added to the EXT hierarchy, 5 added to the PE hierarchy, and 13 added to the MoA hierarchy. The changed concepts count this month is due to 8 concept name changes: Bile-acid Binding Resin [EXT] was changed to Bile Acid Binding Resin [EXT]; Interleukin 1 Receptor Antagonist [EXT] was changed to Interleukin-1 Receptor Antagonist [EXT]; Interleukin 2 Receptor Blocking Antibody [EXT] was changed to Interleukin-2 Receptor Blocking Antibody [EXT]; Interleukin 2 Receptor-directed Cytotoxin [EXT] was changed to Interleukin-2 Receptor-directed Cytotoxin [EXT]; Serotonin 1b and 1d Receptor Agonist [EXT] was changed to Serotonin-1b and Serotonin-1d Receptor Agonist [EXT]; Serotonin 3 Receptor Antagonist [EXT] was changed to Serotonin-3 Receptor Antagonist [EXT]; Serotonin 4 Receptor Antagonist [EXT] was changed to Serotonin-4 Receptor Antagonist [EXT]; and Thyroid Peroxidase Inhibitors [MoA] was changed to Iodide Peroxidase Inhibitors [MoA]. 136,051 total concepts 69 new concepts 8 changed concepts 0 concepts removed ----------------------------------------------------------------- July 2008 NDF-RT (version name 2008.07.08) This release of NDF-RT Public Edition contains 85 new concepts: 67 added to the EXT hierarchy, 4 added to the PE hierarchy, and 14 added to the MoA hierarchy. The changed concepts count this month is due to 8 concept name changes: Corticotropin Releasing Hormone Alteration [PE] was changed to Corticotropin Releasing Hormone Alteration [PE]; Decreased Folic Acid Modification [PE] was changed to Decreased Folic Acid Modification [PE] to strip out extra spaces in the concept name; Decreased Vitamin Uptake and Modification [PE] was changed to Decreased Vitamin Uptake and Modification [PE], also to remove extra spaces; GI Bulking Activity [MoA] was changed to Stool Bulking Activity [MoA]; Hydrogen Ion Scavenging [MoA] was changed to Alkalinizing Activity [MoA]; Neurokinin 1 Antagonist [MoA] and Sulfate Donor [MoA] were both made plural; and Surfactants [MoA] was changed to Surfactant Activity [MoA]. The large removed concepts count this month is due to the removal of the Biologic Structures of Recipient [Genomics] hierarchy, which will no longer be included in the Public Edition of NDF-RT going forward. 135,982 total concepts 85 new concepts 8 changed concepts 127 concepts removed ----------------------------------------------------------------- June 2008 NDF-RT (version name 2008.06.10) This release of NDF-RT Public Edition contains 25 new concepts: 19 added to the EXT hierarchy, 1 added to the PE hierarchy, and 5 added to the MoA hierarchy. The changed concepts count this month is due to 4 concept name changes: H1 Receptor Antagonist [EXT] was changed to Histamine-1 Receptor Antagonist [EXT]; H1 Receptor Inhibitor [EXT] was changed to Histamine-1 Receptor Inhibitor [EXT]; the [PE] tag was added to Peripheral Nervous System Activity Alteration; and TNF Blocker [EXT] was changed to Tumor Necrosis Factor Blocker [EXT]. 136,024 total concepts 25 new concepts 4 changed concepts 0 concepts removed ----------------------------------------------------------------- May 2008 NDF-RT (version name 2008.05.13) This release of NDF-RT Public Edition contains 77 new concepts: 44 added to the EXT hierarchy, 13 added to the PE hierarchy, 18 added to the MoA hierarchy, and 2 added to the Chemical/Ingredient hierarchy. Part of the large new concepts count is due to a reorganization of the Nervous System PE hierarchy. The changed concepts count this month is due to 4 concept name changes: Chemical Structures for Pharmacologic Classification [Chemical/Ingredient] was changed to Chemical Classes for Pharmacologic Classification [Chemical/Ingredient]; Neurological & Neuromuscular System Activity Alteration [PE] was changed to Nervous System Activity Alteration [PE]; NMDA Receptor Antagonist [MoA] was made plural; and Striated Muscle Alteration [PE] was changed to Striated Muscle Metabolic Alteration [PE]. 135,999 total concepts 77 new concepts 4 changed concepts 0 concepts removed ----------------------------------------------------------------- April 2008 NDF-RT (version name 2008.04.08) This release of NDF-RT Public Edition contains 10 new concepts: 24 added to the EXT hierarchy, 7 added to the PE hierarchy, and 4 added to the MoA hierarchy. The changed concepts count this month is due to two concept name changes. The old concept name Alcohol Dehyrogenase Inhibitors [MoA] was changed to include "Dehydrogenase", the correct spelling. The concept Angiotensin-Converting Enzyme Inhibitors [MoA] was changed to make "-Converting" lowercase for consistency with other hyphenated NDF-RT concept names. 135,922 total concepts 35 new concepts 2 changed concepts 0 concepts removed ----------------------------------------------------------------- March 2008 NDF-RT (version name 2008.03.11) This release of NDF-RT Public Edition contains 10 new concepts: 8 added to the EXT hierarchy, and 2 added to the MoA hierarchy. The changed concepts count this month is due to concept name changes. Instances of the acronym "GNRH" in 4 existing concept names in the PE hierarchy were changed to "GnRH". In addition, the following changes to EXT concept names were made, with the former concept names retained as synonyms: Angiotensin 2 Receptor Blocker [EXT], Phosphodiesterase 3 Inhibitor [EXT], and Phosphodiesterase 5 Inhibitor [EXT] were renamed to include Roman numerals, to replicate the original pharmacologic class requested phrases; Greek letters in the concept names Interferon Alpha [EXT] and Interferon Gamma [EXT] were lowercased; and GnRH Secretion Inhibitor [EXT] was changed to reflect the fully-specified name Gonadotropin Releasing Hormone Secretion Inhibitor [EXT]. 135,887 total concepts 10 new concepts 12 changed concepts 0 concepts removed ----------------------------------------------------------------- February 2008 NDF-RT (version name 2008.02.12) This release of NDF-RT Public Edition contains 41 new concepts: 13 added to the EXT hierarchy, 11 added to the MoA hierarchy, and 17 added to the PE hierarchy. The changed concepts count is due to subtree reorganization under the new concept Autonomic Nervous System Activity Alteration [PE]. In addition to this hierarchy reorganization, a second parent was given to any legacy neurotransmitter-specific sympathetic/parasympathetic activity concepts in the new subtree. Finally, a number of concept names containing "Norepinepherine" were changed to reflect the correct spelling. 135,877 total concepts 41 new concepts 37 changed concepts 2 concepts removed ----------------------------------------------------------------- January 2008 NDF-RT (version name 2008.01.08) This release of NDF-RT Public Edition contains changes reflecting decisions made at the November 2007 SPL IEP face-to-face meeting. The former Additional FDA Pharmacologic Classes for SPL hierarchy has been renamed to "External Pharmacologic Classes", and now contains new concepts whose names replicate each pharmacologic class string received. These concepts are mapped via role relationships to appropriate MoA, PE, or Chemical/Ingredient concepts. All concepts in this hierarchy have the tag [EXT] appended to their names, replacing the former [FDA SPL] tag. In addition to new concepts created manually in this hierarchy to reflect recent SPL IEP decisions, 61 concepts were added programmatically from former FDA_SPL_Name property values that existed for those NDF-RT concepts considered to be one-to-one maps to SPL pharmacologic class phrases. These EXT concept names exactly replicate the former FDA_SPL_Name property values. All existing FDA_SPL_Name property values were then removed, and as this property will no longer be used, the property type has been removed entirely from NDF-RT. In addition to these 61 concepts added programmatically, there were 72 new concepts added to the EXT hierarchy based on submissions from the Antimicrobial/Transplant/Hematology FDA list. Other new concepts included 6 added to the Chemical/Ingredient hierarchy, 5 added to the PE hierarchy, and 11 added to the MoA hierarchy. The changed concepts count is due to 14 MoA concepts, which were renamed for consistency to include "Activity" instead of "Agents", "Preparations", or "Scavengers", and one concept whose former name contained an incorrect spelling. Additionally, 29 existing concepts in the EXT (formerly Additional FDA Pharmacologic Classes for SPL) hierarchy were renamed, removing the [FDA SPL] tag and adding the new [EXT] tag. The concept Influenza Neuraminidase Inhibitors [MoA] was retired. The newly-created concept Influenza Neuraminidase Inhibitor [EXT] retains this former concept's NUI. 135,838 total concepts 145 new concepts 43 changed concepts 1 concept removed ----------------------------------------------------------------- November 2007 NDF-RT (version name 2007.11.13) This release of NDF-RT Public Edition contains 11 new concepts: 4 added in the Additional FDA Pharmacologic Classes for SPL list, 6 added to the MoA hierarchy, and 1 added to the Chemical/Ingredient hierarchy. The changed concepts count is due to two renamed MoA concepts, Tumor Necrosis Factor Alpha Receptor Blocking Activity [MoA], and Tumor Necrosis Factor Beta Receptor Blocking Activity [MoA]. 135,684 total concepts 11 new concepts 2 changed concepts 0 concepts removed ----------------------------------------------------------------- October 2007 NDF-RT (version name 2007.10.09) This release of NDF-RT Public Edition contains 17 new concepts: 8 added in the Additional FDA Pharmacologic Classes for SPL list, 1 added to Supplementary Chemicals [Chemical/Ingredient], 1 added to the PE hierarchy, 5 added to the MoA hierarchy, and 2 added to the Chemical/Ingredient hierarchy. An official NDF-RT SPL IEP decision was made to add a second FDA_SPL_Name, beta-Adrenergic Receptor Inhibitor, to the concept Adrenergic beta-Antagonists [MoA], which was mapped to both the New Products pharm. class phrase with the same string and the Cardiac/Renal submission beta-adrenergic blocker. Going forward, this approach will ONLY be used when the FDA_SPL_Name values are true synonyms. 135,673 total concepts 17 new concepts 0 changed concepts 0 concepts removed ----------------------------------------------------------------- August/September 2007 NDF-RT (version name 2007.08.31) This full release of NDF-RT Public Edition contains the new "Additional FDA Pharmacologic Classes for SPL" list under "Pharmaceutical Preparations". Its 16 assigned children were created in response to requests for concepts to support the FDA Structured Product Labeling (SPL) initiative. Concepts in this group represent specific requests for SPL Pharmacologic Class phrases that can not be represented by a single new or existing MOA, PE or CS NDF-RT concept. This includes phrases that represent therapeutic intent as defined by the FDA SPL initiative, as well as those represented by the concatenation of multiple NDF-RT concepts, and in rare cases ideas that did not fit elsewhere within NDF-RT. None of the concepts in this new group are listed in the MOA, PE or CS SPL files published separately but many have defining role relationships to one or more MOA, PE and CS concepts. The changed concepts count includes concepts changed for remodeling of the Nucleic Acid Synthesis Inhibitors [MoA], Protease Inhibitors [MoA], and Kinase Inhibitors [MoA] subtrees, as well as concepts affected by new FDA_SPL_Name algorithm, and two concepts renamed due to misspellings. Fms-like tyrosine kinase (FLT) Inhibitors [MoA] was removed after determining that it was not used as a role value for NDF-RT drug modeling. 135,656 total concepts 17 new concepts 78 changed concepts 1 concept removed ----------------------------------------------------------------- July 2007 NDF-RT (version name 2007.07.10) This Full release of NDF-RT Public Edition contains no added concepts based on FDA submissions for SPL. Changes in this version of NDF-RT occurred solely due to a few changes and 85 additional mappings of NDF-RT Disease concepts that already had at least one existing SNOMED CT mapping. None of these were on the current SPL Problem List (Jan. 2007). These changes resulted in the creation of at least one additional map from that Disease concept to a SNOMED CT concept on the SPL Problem List. A map (recorded as a property on the concept) to a SNOMED CT concept on the SPL Problem List will now be called the SPL_Problem_List_Mapping_ID. In addition, the existing SNOMED_ID property was renamed to SNOMED_Mapping_ID. This final change resulted in the large changed concept count. 135,640 total concepts 0 new concepts 2478 changed concepts ----------------------------------------------------------------- June 2007 NDF-RT (version name 2007.06.12) This Full release of NDF-RT Public Edition contains changes derived from SPL Pharmacologic Class requirements plus changes derived from a re-synchronization of the Chemical/Ingredient hierarchy with the current version of MeSH (2007). 135,640 total current concepts 324 new concepts 33 changed concepts 21 deprecated concepts (reflects semantic duplicates noted either due to formal SPL decisions or MeSH refresh QA process. Prior meanings and NUIs of these concepts are attributed to existing NDF-RT concepts.) A substantial reduction in the number of synonyms is reflected in this release due to the improved accuracy of synonym assignment based on UMLS Metathesaurus. Removed synonyms were all from the Chemical/Ingredient hierarchy. Chemicals and Ingredients concepts were derived from 2007 ASCII MeSH files. ----------------------------------------------------------------- May 2007 NDF-RT (version name 2007.05.08) Starting with the May 2007 release a new property has been created: FDA_SPL_Name. This property will only be added to concepts when there is requirement for a concept representation (IE: a term name) preferred for SPL use that is not the existing “preferred name” for the concept. The value of the FDA_SPL_Name property may be an existing synonym, or it may be a new term representation. If it is new, it will only be additionally added as a synonym for concepts NOT derived from MeSH. This was done to keep synonyms algorithmically consistent with the UMLS MeSH synonym list for that concept (as noted above.) Only concepts requiring these additions will carry this property. This means that any SPL user must determine if that property exists for a concept and use the value as the concept preferred name. This Full release of NDF-RT Public Edition contains only a few changes modeled and approved by the ICCB committee. 135,337 total current concepts 6 new concepts 1 changed concept 1 retired concept Chemicals and ingredient concepts were derived from MeSH 2006 (2006_05_01) ----------------------------------------------------------------- April 2007 NDF-RT (version name 2007.04.10) This Full release of NDF-RT Public Edition contains only a few changes modeled and approved by the ICCB committee. 135,332 total current concepts 10 new concepts 1 changed concept 1 retired concept Chemicals and ingredient concepts were derived from MeSH 2006 (2006_05_01) ----------------------------------------------------- March 2007 NDF-RT (version name 2007.03.13) As of the March, 2007, the provision of NDF-RT content outside the VA system will not include elements deemed only of value to internal VA operations. This "extract" will be known as the NDF-RT Public Edition and will contain all of the core NDF-RT concepts that existed in previous releases and all concept NUIs will remain unchanged. In essence the Public Edition only removes selected VA-specific properties, qualifiers, associations and a few Kinds that represented information required for unique internal VA activities. All Roles remain unchanged. These changes are expected to have no impact on non-VA use of the NDF-RT. Listed below are the changes implemented beginning with this release. *********************************************** **ELEMENTS PRESERVED IN NDF-RT PUBLIC EDITION** *********************************************** NDF_KIND {formerly DRUG_KIND} INGREDIENT_KIND MECHANISM_OF_ACTION_KIND PHYSIOLOGIC_EFFECT_KIND PHARMACOKINETICS_KIND DISEASE_KIND RECIP_STRUCTURES_KIND RXNORM_DOSE_FORM_KIND Source -> Target has_Ingredient NDF_KIND --> INGREDIENT_KIND CI_ChemClass NDF_KIND --> INGREDIENT_KIND metabolized_by NDF_KIND --> INGREDIENT_KIND has_active_metabolites NDF_KIND --> INGREDIENT_KIND effect_may_be_inhibited_by NDF_KIND --> NDF_KIND metabolized_by_recip_structure NDF_KIND --> RECIP_STRUCTURES_KIND gene_encodes_for RECIP_STRUCTURES_KIND --> INGREDIENT_KIND gene_has_variant RECIP_STRUCTURES_KIND --> RECIP_STRUCTURES_KIND gene_encodes_for_enzyme RECIP_STRUCTURES_KIND --> RECIP_STRUCTURES_KIND has_MoA NDF_KIND --> MECHANISM_OF_ACTION_KIND CI_MoA NDF_KIND --> MECHANISM_OF_ACTION_KIND has_PE NDF_KIND --> PHYSIOLOGIC_EFFECT_KIND CI_PE NDF_KIND --> PHYSIOLOGIC_EFFECT_KIND has_PK NDF_KIND --> PHARMACOKINETICS_KIND site_of_metabolism NDF_KIND --> PHARMACOKINETICS_KIND may_treat NDF_KIND --> DISEASE_KIND may_prevent NDF_KIND --> DISEASE_KIND may_diagnose NDF_KIND --> DISEASE_KIND induces NDF_KIND --> DISEASE_KIND CI_with NDF_KIND --> DISEASE_KIND has_DoseForm NDF_KIND --> RXNORM_DOSE_FORM_KIND Heading_Mapped_To INGREDIENT_KIND --> INGREDIENT_KIND VA_Product_Component NDF_KIND --> NDF_KIND VA_Secondary_Drug_Class NDF_KIND --> NDF_KIND VA_Strength VA_Unit NUI Display_Name Synonym Level Status Status_Change_Date Review_Status MeSH_Name MeSH_UI Included_MeSH_UIs MeSH_Definition MeSH_Pharmacologic_Action NCI_Preferred_Term RxNorm_CUI RxNorm_Code RxNorm_Name RxNorm_Preferred_Translation_Term SNOMED_ID UNII UMLS_CUI UMLS_Semantic_Type UMLS_Preferred_Translation_Term VUID VA_Class_Description VA_Class_Code VA_Class_Type VA_CS_Federal_Schedule VA_Manufacturer_Code VA_National_Formulary_Name VA_NDC VA_NDF_Type VA_Product_Code VA_Package_Code VA_Print_Name VA_RxOtc_Indicator VA_Strength VA_Trade_Name VA_Units VA_UPN Date Status VUID *********************************************************** **VA-SPECIFIC ELEMENTS REMOVED FROM NDF-RT PUBLIC EDITION** *********************************************************** EXTERNAL_REFERENCE_KIND VA_DISPENSE_UNITS_KIND VA_DOSE_FORMS_KIND VA_DRUG_INTERACTION_KIND VA_DRUG_MANUFACTURER_KIND VA_DRUG_UNIT_KIND VA_NATIONAL_FORMULARY_RESTRICTION_KIND VA_PACKAGE_SIZE_KIND VA_PACKAGE_TYPE_KIND VA_ROUTE_OF_ADMINISTRATION_KIND External_Dispense_Unit External_Dose_Form External_Package_Size External_Package_Type External_ROA VA_Dispense_Units VA_Dose_Form VA_Dose_Form_Units VA_Drug_Manufacturer VA_Ingredient_1 VA_Ingredient_2 VA_National_Formulary_Restriction VA_Package_Size VA_Package_Type VA_ROA FILE IEN PACKAGE Search_Name Last_Reviewed Reviewed_By Comment Alert VA_Abbreviation VA_Discontinue VA_Dispense_Units_Per_Dose VA_Dose_Form_Print_Name VA_Drug_Identifier VA_DSS_Number VA_Exclude_Drug_Interaction_Check VA_File VA_IvFlag VA_Max_Cumulative_Dose VA_Max_Daily_Dose VA_Max_Single_Dose VA_Min_Daily_Dose VA_Min_Single_Dose VA_Nationally_Entered VA_National_Formulary_Indicator VA_NDT_XML VA_Package_Use VA_Product_Identifier VA_Severity VA_Single_or_Multi_Source_Product VA_Total_Indexes VA_Transaction_History VA_Transmit_to_CMOP VA_User_Lock VA_Workflow_Comment VA_Workflow_Status User Name VA_Class_Description_Line VA_File VA_IEN VA_PACKAGE NDF-RT Public Edition Release notes Created on 3/23/07